

via Giustiniani, 2
35128 Padova
dipartimento.medicinadimed@pec.unipd.it
C.F. 80006480281
P.IVA 00742430283
www.medicinadimed.it

Padova, 2 April, 2020

To whom it may concern:

It is with great pleasure that I submit this letter of recommendation in my capacity of Director of the Department of Laboratory Medicine of the University-Hospital of Padova, Italy


2019-nCoV (official name is SARS-CoV-2) has infected more than 860,000 people in the world and caused a serious global outbreak. World Health Organization declared the crisis of 2019-nCoV (SARS-CoV-2) as a Public Health Emergency of International Concern and COVID-19 was characterized as a pandemic. With the increasing infected number of Novel Coronavirus, early diagnosis and early treatment to minimize the spread of the coronavirus has become a priority.

In my department we have been using Snibe MAGLUMI CLIA system for 7 years. Considering that the COVID-19 outbreak is spreading worldwide, and Italy is particularly involved in this dramatic pandemic, now we are using MAGLUMI® 2019-nCoV IgG/IgM CLIA assays to assist the diagnosis and monitoring of SARS-CoV-2.

In particular, I would like to inform you that we have adopted the Snibe CLIA systems for 2019-nCoV IgG/IgM for a screening program in the Veneto Region after validating the method and comparing the validation data to the sensitivity and specificity declared by Snibe, thus demonstrating the valuable clinical performances of the assays.

Should you have any further questions on the performance of the above mentioned Snibe MAGLUMI system, do not hesitate to contact me.

Best Regards,


Mario Plebani

.....
Full Professor of Clinical Biochemistry and
Clinical Molecular Biology
School of Medicine University of Padova
Director, Department of Laboratory Medicine
University-Hospital of Padova